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Stuart H. Orkin2,*I am enormously grateful to The American Society of Hu-
man Genetics (ASHG) for selecting me to join the distin-
guished roster of recipients of the William Allan Award. I
especially thank Haig Kazazian, a former recipient and a
wonderful collaborator in the early days of my indepen-
dent career, for the nomination and the gracious introduc-
tion today. I am not a conventional awardee for this honor,
given that I have never held an appointment in a genetics
department or division. Instead, my research career devel-
oped in a division of hematology. I have always thought of
myself as a geneticist, and I accept the recognition by the
ASHG as confirmation of this suspicion.
Reflecting on my career, I realize that I have been privi-
leged to live through successive waves in the revolution
of biology over the past three plus decades. My interest
in molecular biology and genetics was kindled in my sec-
ond year at the Massachusetts Institute of Technology
(MIT) in an introductory biology course given by Salvador
Luria (Figure 1). This was not the biology I knew from high
school, which involved cutting up frogs and memorizing
phyla. Luria captured the excitement of the early days of
molecular genetics and took a special interest in under-
graduates. Stimulated by this course, I chose to major in
biology, or life sciences as it is called at MIT. In that era,1This article is based on the address given by the author at the meeting of The
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or physics, because the true revolution in the biological sci-
ences was still a decade or so into the future. Besides Luria, I
encountered many other luminaries as professors,
including Boris Magasanik and Vernon Ingram, who intro-
duced us to the single amino acid substitution in sickle he-
moglobin.1 At one meeting of Ingram’s course, he invited
guest lecturers from the Karolinska Institute in Stockholm
to speak, and all I recall is that their presentation might
well have been delivered in Swedish. In retrospect, I feel
that the Nobel committee sadly overlooked Ingram’s
monumental contribution to human genetics. My educa-
tion at MIT was enriched in other ways. Although I
wouldn’t have predicted it at the time, Bob Weinberg
and David Botstein, my teaching assistants in the intro-
ductory biology course, would become superstars in the
coming years.
Because my father was a devoted old-time surgeon who
saw each patient as a potential friend rather than a disease
subject, I sought ways to link my early experiences in mo-
lecular genetics with medicine. Hence, I crossed the
Charles River to attend Harvard Medical School (HMS).
Although I might have pursued both the MD and PhD de-
grees, in those days Harvard wouldn’t permit it; they said
that one Harvard degree was enough for Kornberg, and
therefore it is sufficient for any student! We were encour-
aged to take a year off from medical school for research if
we were so inclined. After my second year, I chose to
work with John Littlefield at Massachusetts General Hospi-
tal and spent a wonderful year immersing myself in the
field of somatic cell genetics. As I re-entered the third
year at HMS, I knew I would return to research.
During my junior year at HMS, as US military commit-
ment in Southeast Asia accelerated, the NIH announced a
plan by which if one committed to a 2-year tour of duty
in the Public Health Service (PHS), Uncle Sam would pay
for the final year of medical school. Besides carrying the
allure of the NIH, the premier training ground for aca-
demic biomedicine at the time, the program provided a
generous stipend during the final year of school, making
an application a no-brainer. Having heard positive reports
from Richard Erbe and David Livingston on cutting-edgeAmerican Society of Human Genetics (ASHG) on October 20, 2014, in San
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Figure 1. Three Influential Mentors in My Careerresearch led by Phil Leder (Figure 1), I applied to and was
matched to his laboratory in a small building on the NIH
campus. In accord with the PHS program, I spent a year
as an intern in pediatrics at Boston Children’s Hospital
prior to moving to Bethesda. Free of virtually any other re-
sponsibilities for 2 years at the NIH, I devoted myself to
learning the emerging techniques and concepts of molec-
ular biology. I learned how to purify messenger RNA
hand in hand with Leder after bleeding hundreds (yes,
hundreds!) of mice, prepare reverse transcriptase from in-
fected chicken blood, and purify restriction enzyme
EcoRI—all ancient history to current trainees in molecular
biology. I learned how to think about doing clean, direct
experiments to answer specific questions without relying
on a kit from a biomedical supplier (none of which existed
at the time). I cut my teeth on mouse erythroleukemia
cells, a convenient model of red cell differentiation, which
we still use today for many genomic experiments. What we
hoped to learn in my subgroup of the Leder laboratory was
how globin messenger was expressed, even though we
didn’t have a clue that the structure of globin genes (or
other mammalian genes) wasn’t simple and unbroken, as
we imagined then. My experience in the Leder laboratory
set me onmy lifelong quest to understand blood cell devel-
opment and apply this knowledge where possible to hu-
man disease.
As I was exiting the Leder laboratory, we were just begin-
ning to use restriction enzymes to fractionate genomic
DNA in the hopes of purifying globin genes. There was
considerable discussion as to whether we might actually
be able to purify a gene by standard biochemical purifica-
tion schemes. I surrendered my laboratory bench to Shir-
ley Tilghman, who accomplished the cloning of the
mouse globin genes soon thereafter with the early lambda
phage vectors. As I was leaving the NIH, I considered
entering either human genetics or hematology as my pri-
mary field for a fellowship. Ultimately, I chose to return
to Boston Children’s Hospital for a second clinical year
in pediatrics and join a rather newly formed program in
pediatric hematology and oncology led by David Nathan
(Figure 1), now recognized as a true giant in academic
medicine. As I was midway through my clinical year,
Nathan informed me that Bernie Forget, an early pioneer
with another HMS student, Ed Benz, in hemoglobin mo-The Amelecular biology, was moving to Yale and that I was to be
given his laboratory space. I was instructed to write to
the NIH and March of Dimes for grant support to establish
an independent lab. Not knowing any better, I did this.
Although too naive at the time to understand how risky
starting a lab might be without further training, I am grate-
ful to Nathan for giving me an opportunity to be indepen-
dent at an age when most trainees now are just beginning
their postdoctoral training. I chose to focus on the red cell
and its major disorders and address the following ques-
tions: How are these cells made during development?
How are red cells programmed from hematopoietic stem
cells? How do red cells or other blood cells go awry in dis-
ease? What can we do to alleviate suffering from blood dis-
orders? In this quest, my career transitioned sequentially
through the introduction of recombinant DNA methods,
prenatal diagnosis of disease by DNA analysis, positional
cloning, stem cell biology, the new genetics of genome-
wide association studies (GWASs), and now genome
engineering. In many respects, my history traces that of
modern biomedical science.
With my newly established laboratory, I first set out to
understand the mutations that lead to under-expression
or no expression of b-globin in b-thalassemia and hoped
that this path would provide clues to the mysteries of the
disorder but also how red blood cells are made. At the
time, it was believed that determining the globin gene mo-
lecular defects that lead to thalassemia would provide spe-
cial insights into cell-specific gene expression. In my
growing laboratory, we learned lambda phage cloning of
genomic DNA, now a relic of the past, and set out to clone
the b-globin gene of patients with b-thalassemia. It was at
this juncture that I was fortunate to partner with Haig Ka-
zazian, who had defined haplotypes (or frameworks) of the
b-globin gene cluster by restriction enzyme mapping.2 He
hypothesized that thalassemia mutations occurred in the
context of these haplotypes and, therefore, that each
haplotype would be associated with a specific thalassemia
gene mutation. The next several years were devoted to a
comprehensive effort to clone b-thalassemia genes succes-
sively from different haplotypes in several different
geographic or ethnic groups, work that led to validation
of the Kazazian hypothesis and to the nearly complete
description of b-thalassemia at the molecular level3,4
(Figure 2). Mutations reside in virtually every part of the
gene: promoter, coding region, splice sites, and the poly(A)
addition signal. Save for a couple of rather rare promoter
mutations, none, however, affected cell-specific aspects
of gene expression. It was an exciting era. Without fax ma-
chines, computers, or cell phones, Haig and I communi-
cated almost daily by phone to discuss our experiments.
Although we took great satisfaction in the comprehensive
dissection of mutations in a human disorder for the first
time, I had a nagging sense that we didn’t quite get to
the core of how a red cell is orchestrated at the molecular
level or how we could use our new knowledge to treat
patients.rican Journal of Human Genetics 96, 354–360, March 5, 2015 355
Figure 2. Mutations in the b-Globin
Gene in b-Thalassemia
Figure 3. Areas in which Study of GATA-1 Provided Insights into
Biology or DiseaseNonetheless, knowing the specific defects responsible
for b-thalassemia had a major practical benefit in that it
enabled prenatal diagnosis of disease by DNA analysis. In
the early days, this was accomplished by Southern blot
analysis (where possible) or with oligonucleotide hybridi-
zation. Of course, newer methods, such as PCR, rapidly
replaced older technology. Where applied in endemic re-
gions, such as the island of Sardinia, prenatal diagnosis
of thalassemia has been enormously successful and virtu-
ally eradicated new births of affected individuals.
While thinking about what to do next to address funda-
mental issues in blood cell development, I took a gratifying
detour in collaboration with Lou Kunkel and his MD-PhD
student TonyMonaco in the positional cloning of the gene
defective in a classic X-linked immune deficiency, chronic
granulomatous disease (CGD),5 a disorder that Nathan and
colleagues at Boston Children’s Hospital had studied for
many years. Although the task of cloning the gene might
seem simple by current standards, at the time we could
not take advantage of PCR (which had not come on the
scene yet) or large-scale DNA sequencing. Instead, we
relied on brute force and lots of luck. As often happens af-
ter the cloning of a new gene, identification of the gene
mutated in CGD led to important insights into the phago-
cyte oxidase system, a major host defense system of white
blood cells.
With my heart in trying to understand how blood cells
are programmed, hoping that this path might lead to in-
sights into therapy of the major hemoglobin disorders
(Figure 4), I then turned to the nucleus in search of the crit-
ical transcriptional regulators that determine blood cell
fate. Because we already recognized at the time that having
more fetal hemoglobin (HbF) was beneficial to those with
the major hemoglobinopathies, we first focused on a
region of one of the g-(fetal) globin promoters where sin-
gle-base changes were known to greatly increase expres-
sion of the g-gene in cis. Such hereditary persistence of
fetal hemoglobin (HPFH) mutations was a mystery then
and is largely still a mystery in terms of how the mutations
lead to a 10- to 50-fold increase in gene expression. None-
theless, we found by conventional gel shift assay a nuclear
factor that bound over one of these HPFH regions.6 We356 The American Journal of Human Genetics 96, 354–360, March 5, 2015ultimately cloned its cDNA, which
encodes the protein GATA-1, the
foundingmember of the GATA family
of transcription factors.7 GATA-1 is a
master regulator of erythroid gene
expression. Over the past 25 years,
studies of its roles in different con-
texts have provided a window into
extraordinarily diverse biology,
including lineage differentiation,lineage choice, lineage reprogramming, rare diseases of
red cells and megakaryocytes, and leukemogenesis
(Figure 3). Also, GATA-1 led to the discovery of the related
GATA factors (GATAs 2–6), which in aggregate are involved
in nearly all organ systems and many disease entities.
Using the emerging technology of homologous recombi-
nation in embryonic stem cells and the generation of
knockout mice,8 we then proceeded to identify and inacti-
vate numerous nuclear factors that determine blood stem
cell or lineage-restricted development9 (Figure 4). The
knowledge gained from this approach led to a deeper un-
derstanding of the factors involved in specification of he-
matopoietic stem cells, differentiation of blood lineages,
and the close relationship between normal and malignant
hematopoiesis.10 Most notably, virtually all of the essential
transcription factors that drive hematopoiesis have been
corrupted by translocations or mutations to engender leu-
kemia. An underappreciated aspect of the studies of he-
matopoietic transcription factors in the 1990s and early
2000s was the finding that introduction of individual fac-
tors into committed blood lineages could reprogram one
lineage to another. In my view, experiments of this type,
largely pioneered by Thomas Graf,11,12 set the stage
Figure 4. Transcription Factor Require-
ments in Hematopoietic Development
Asterisks indicate those factors associated
with hematopoietic malignancies through
overexpression, mutation, or
translocation.
Figure 5. Pattern of Hemoglobin Gene Expression during
Ontogenyfor the revolution of somatic cell reprogramming by
Yamanaka.13
A central problem remained unsettled. How might we
employ what we learn in molecular biology to the major
hemoglobin disorders? Although sickle cell disease (SCD)
was described more than 100 years ago and has served as
a ‘‘poster child’’ for a molecular disease caused by a point
mutation for more than 50 years,1 none of the current
management of patients has benefited from our genetic
understanding. All therapy is directed at the primarymuta-
tion’s secondary and tertiary consequences, including
vascular and organ damage and anemia resulting from
polymerization of the altered hemoglobin. Although
SCD has not merited the attention it deserves, in my
opinion, the problem is global in that it is estimated that
there will be more than five million children with SCD
on the African continent in the next decade. Taken
together with SCD in other regions and b-thalassemia in
many parts of the world, the hemoglobinopathies are a
global public-health burden, growing rather than
decreasing in impact.
Apart from repairing the sickle or thalassemia mutations
by gene editing, which is not yet possible because of the
low frequency of homologous recombination in hemato-
poietic stem cells, perhaps the most promising strategy
that has been pursued is reactivation of HbF in adults,
given that HbF can entirely replace b-containing adult he-
moglobin with no ill effects and HbF is an outstanding in-
hibitor of the sickling process. The switch from fetal to
adult hemoglobin is a paradigm of developmental, cell-
specific gene expression—one that is taught in introduc-
tory biochemistry and genetic courses (Figure 5). Natural
history studies of an NIH cohort demonstrated the benefit
of higher HbF for survival.14 Although the DNA sequence
of the human b-gene cluster has been on hand for more
than 30 years, the sequence alone provided no insights
into the critical switch. What was learned about GATA-1The American Journal of Humanand erythroid gene expression per-
tains equally well to fetal and adult
gene expression. The study of HbF
has a long history, starting in the
1950s and 1960s with family studies
documenting that the level of HbF is
genetically determined and that
increased HbF relieves the conse-
quences of SCD or b-thalassemia.
Despite intensive efforts by many lab-
oratories to find stage-specific tran-
scription factors that might accountfor the switch, the basis remained a mystery until quite
recently.
The breakthrough for the field came with the applica-
tion of GWASs to the analysis of HbF levels in popula-
tions. Two GWASs were performed: one in England by
Thein and the other in Sardinia by the late A. Cao and
his colleagues, with whom we were fortunate to collabo-
rate.15,16 The ‘‘we’’ here includes Joel Hirschhorn and
Guillaume Lettre—true geneticists, not hematologists
like me—and a gifted MD-PhD student in my group, Vijay
Sanakran, who doggedly pursued re-activating my own
interest in HbF control. The results of these GWASs were
stunning in their simplicity: we observed only three ma-
jor ‘‘hits,’’ including one within the b-locus and one
near c-MYB, which was previously suggested as a candi-
date regulator (Figure 6). The remaining new hit resided
on the short arm of chromosome 2 at the locus encoding
BCL11A, a previously identified transcriptional repressor
essential for B-lymphoid cell development but totallyGenetics 96, 354–360, March 5, 2015 357
Figure 6. Manhattan Plot of GWAS for HbF Levels in NIH Cohort
with SCD
Figure 7. BCL11A as a Quantitative Regulator of HbF Levelsunsuspected as a regulator in erythroid cells. Remarkably,
the genetic contribution of the three hits accounts for
~50% of the total genetic variation in HbF.17 In the US
SCD population, high HbF status at BCL11A leads to a
modest increase in HbF from about 3% to 11%, a meas-
ureable increase but well below the level at which symp-
toms of disease are regularly ameliorated. Through a series
of studies in cells and mice, my group has validated
BCL11A as a central regulator of Hb switching in mice
and HbF silencing in humans.18,19 Dial BCL11A up, and
HbF is reduced; dial down BCL11A, and HbF is increased
(Figure 7). Indeed, erythroid-specific inactivation of
BCL11A in humanized SCD mice completely ablates
phenotypic consequences and restores hematology to
normal through reactivation of HbF.18 Remarkably, and
an exception among transcription factors with which I
am aware, loss of BCL11A has no effect on red cell produc-
tion or differentiation—it has an effect only on the type
of hemoglobin within the mature cells. This curious
happenstance, I believe, might play an important role in
translating findings to patients.
Having established that BCL11A is a major and perhaps
the central regulator of the hemoglobin switch and HbF
silencing, we were left to account for what GWAS-identi-
fied genetic variation at the BCL11A locus signified. This
is often the point at which studies of GWAS-identified
loci meet insurmountable obstacles. In this instance, the
pieces fell into place readily with the tools available to us
in terms of prior knowledge of globin gene expression
and red cell biology. The critical SNPs associated with358 The American Journal of Human Genetics 96, 354–360, March 5HbF levels are clustered within a large intron of BCL11A,
suggesting that genetic variation would affect expression
rather than the structure of the protein.20 Indeed, no ge-
netic variation within the coding portion of BCL11A has
been observed. The region in which the SNPs cluster ex-
hibits the epigenetic hallmarks of a putative regulatory
element, marked by appropriate histone modifications
and DNase hypersensitive sites. Transient transgenic anal-
ysis of a 10-kb segment encompassing the major SNPs
demonstrated erythroid-specific and adult-stage-specific
enhancer function in mice. Further analysis of SNPs
within the region, coupled with additional DNA
sequencing of SCD patients, identified a SNP that accounts
for the majority but not the entirety of the HbF allele sta-
tus. We believe that this is a causal SNP because it alters a
cognate binding site for the two major erythroid transcrip-
tion factors, GATA-1 and Tal-1, and in heterozygous indi-
viduals for high and low HbF alleles leads to a reduction
in allele-specific transcription factor binding and RNA
transcript expression.20 The overall decrease in expression
of BCL11A transcript from the HbF allele is estimated to be
~40%. Therefore, a modest reduction in BLC11A expres-
sion, on the order of 40%, is associated with a rise in
HbF from about 3% to 11% on average in the SCD
population.
Although natural genetic variation leads to a modest
change in HbF, how critical is the enhancer to overall
gene expression? To address this, we turned to the last ma-
jor technology, genome editing. In this instance, we used
modified zinc fingers, TALENS, to remove the enhancer
from mouse erythroid cells. Remarkably, expression of
BCL11A was reduced by >99% in enhancer-deleted
erythroid cells.20 In contrast, deletion in B cells, where
BCL11A is highly expressed, failed to affect expression.
Hence, the enhancer is an essential, erythroid regulatory
element for BCL11A expression. We believe that this
finding is important in considering genes identified
through GWASs. Although the effect size of a particular
SNP to a particular trait or disease might be small, this
does not necessarily indicate that the contribution of
the gene to the biology or disease under study is also
small. Natural genetic variation can only go so far,, 2015
Figure 8. Erythroid Enhancer Element
within BCL11A Controls the Output of
BCL11A and, Therefore, the Level of HbFparticularly if a gene is expressed in multiple cellular con-
texts. The consequences of natural variation and deletion
within the erythroid enhancer of BCL11A are depicted in
Figure 8.
Our finding that the BCL11A erythroid enhancer is crit-
ical to expression only in the red cell lineage forms the ba-
sis for entertaining the possibility of using genetic engi-
neering to inactivate the enhancer in hematopoietic
stem cells as an improved strategy of gene therapy
(Figure 9).20 In this manner, the effects of gene modifica-
tion would be cell restricted and allow for maximal HbF
expression. Recent studies of rare microdeletion syndrome
have shed light on the quantitative relationship between
BCL11A levels and HbF reactivation. Patients with 2p15–
p16.1 deletions display an autism spectrum phenotype
and developmental delay. Remarkably, these individuals,
who are haploinsufficient for BCL11A, have normal hema-
tologic and immunologic function and exhibit steady-
state HbF levels in the 15%–30% range, equivalent to
that of the most potent, classical HPFH mutations (unpub-
lished data). Therefore, we anticipate that editing of the
BCL11A enhancer by current and emerging gene-editing
tools, which often tend to favor homozygous deletions,
will lead to expression of HbF at a level that would most
likely be curative in SCD or thalassemia. Preclinical studiesThe American Journal of Humanto bring gene-editing technology to
patients with hemoglobin disorders
are underway.
No matter how successful genetic
engineering might become, it can
never meet the global health chal-
lenges of hemoglobin disorders.
Indeed, in order to reduce the impact
of these diseases on a global scale, it
will be necessary to develop small
molecules, drugs that can achieve a
sufficient functional reduction inBCL11A (or some other critical component in HbF regula-
tion) to induce curative levels of HbF. This is a major chal-
lenge but is one that modern protein chemistry might be
able to address.
I have been blessed to live through the revolution in
the biomedical sciences over the past three decades.
When I entered the field, we did not know the structure
of genes, nor could we express or sequence a gene if it
were presented to us. We can now see how the deep
knowledge gained can be applied to effect real phenotypic
changes in patients to their benefit. Obviously, we all
stand on the giants who came before, and so today I
feel thankful that I arrived on the scene at a propitious
time. None of the work I described was done alone. I
have had great collaborators at each step along the way,
and remarkably talented trainees, many of whom have
moved on to establish their own independent careers of
note. I am indebted to the NIH and Howard Hughes Med-
ical Institute for their support and to my colleagues at
Boston Children’s Hospital and the Dana Farber Cancer
Institute, who have provided a wonderful and enriching
environment. Finally, I would not be here today if it
were not for unwavering support from my family, espe-
cially my wife, Roslyn, who has been my steadfast support
for 45 years.Figure 9. Gene Therapy by Genome En-
gineering
As in a standard bone marrow transplant,
hematopoietic stem cells are obtained
(either from the bonemarrow ormobilized
into the peripheral blood). Genome engi-
neering using a zinc finger nuclease (ZFN)
or CRISPR/cas9 is then employed to
modify the cells ex vivo. These cells are
then reinfused into the recipient to recon-
stitute the hematopoietic system.
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